MIST Milestone Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

   MONTREAL and CHARLOTTE, N.C., May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

   The pre-recorded fireside chat will become available on Tuesday, May 24, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

   About Milestone …

   View Full Article
2. 12 May 2022 Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update

   -       RAPID topline data readout remains on track for mid-second half 2022

   -       Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions

   MONTREAL and CHARLOTTE, N.C., May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update.

   "The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT," said Joseph Oliveto, President and Chief Executive Officer of…

   View Full Article
3. 30 April 2022 Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT

   - Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention -

   - As in other studies, etripamil was well tolerated by patients -

   - Data to be featured during late breaking session at Heart Rhythm 2022 -

   MONTREAL and CHARLOTTE, N.C., April 30, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced data from NODE-302, its Phase 3 open-label extension study of etripamil nasal spray, the Company's novel, investigational, calcium channel blocker in patients with paroxysmal supraventricular tachycardia (PSVT). The presentation, titled "Etripamil Nasal Spray Is Effective …

   View Full Article
4. 15 April 2022 Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   MONTREAL and CHARLOTTE, N.C., April 15, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted one new employee 65,000 incentive stock options at a per share exercise price of $6.85, the closing price of Milestone's common stock on April 1, 2022 and another new employee 36,000 incentive stock options at a per share exercise price of $6.93, the closing price of Milestone's common stock on April 11, 2022. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants…

   View Full Article
5. 14 April 2022 Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT

   • Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler, MD and Sean Pokorney, MD
   • Conference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ET

   MONTREAL and CHARLOTTE, N.C., April 14, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). Etripamil is currently being assessed in multiple clinical trials, including…

   View Full Article